Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
SEEGENE
FOCUS DIAGNOSTICS, INC.

High Levels of Vascular Endothelial Growth Factor Mark Noncancerous Pancreatic Cysts

By Labmedica International staff writers
Posted on 27 Feb 2014
Image: A benign pancreatic cyst is evident at the tip of the clamp in this photo (Photo courtesy of the Indiana University School of Medicine).
Image: A benign pancreatic cyst is evident at the tip of the clamp in this photo (Photo courtesy of the Indiana University School of Medicine).
A new noninvasive diagnostic test can differentiate benign pancreatic cysts from those that have the potential to progress to invasive pancreatic adenocarcinoma (pancreatic cancer).

Serous cystic neoplasms (SCN) have no malignant potential, but can mimic mucinous pancreatic cysts, which have the potential to progress to invasive pancreatic adenocarcinoma, on imaging. The inability of medical imaging to readily differentiate between these two classes of cysts can result in patients having to go through extensive follow-up medical visits, invasive biopsies, and unnecessary surgery to determine the true nature of their pancreatic cyst.

Investigators at the Indiana University School of Medicine (Indianapolis, USA) hypothesized that vascular endothelial growth factor (VEGF)-A levels in pancreatic fluid might correlate with pathologic diagnosis of the pancreatic cyst. They used an ELISA assay to determine VEGF-A levels in pancreatic cyst fluid taken from 87 patients with suspicious pancreatic growths including pseudocysts, SCN, mucinous cystic neoplasm, low/moderate grade intraductal papillary mucinous neoplasm, high-grade/invasive intraductal papillary mucinous neoplasm, and pancreatic ductal adenocarcinoma.

Analysis of the data revealed that VEGF-A was significantly upregulated in SCN cyst fluid compared with all other diagnoses, and that VEGF-A had 100% sensitivity and 97% specificity as an SCN biomarker.

Senior author Dr. C. Max Schmidt, professor of surgery, biochemistry, and molecular biology at the Indiana University School of Medicine, said, "This is the first cyst fluid protein biomarker that can differentiate serous cystic neoplasms, a benign type of cystic lesion, from all other cancerous or precancerous cystic lesions without surgery."

"Only 15% of pancreatic cancer patients will benefit from surgery, and of those, only about 20% will survive five years," said Dr. Schmidt. "Many of my patients when initially told they have pancreatic cysts are very fearful and ask for surgical removal of the cyst or the entire pancreas before they even learn their options. Now, physicians will have an outpatient procedure to offer that can take some of the guesswork out of the equation.”

The study was published in December 24, 2013, online edition of the Journal of the American College of Surgeons.

Related Links:

Indiana University School of Medicine



PURITAN MEDICAL
ADVANCED INSTRUMENTS
GREINER-BIO-ONE
BioConferenceLive

Channels

Genetic Tests

view channel
Image: The QuantiTect Reverse Transcription Kit (Photo courtesy of Qiagen)

Blood Tests Predict Risk of Sudden Cardiac Death

A simple blood test can predict a person's risk for sudden cardiac death, enabling physicians to quickly and accurately assess a patient's need for an implantable cardiac defibrillator (ICD).... Read more

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Industry News

view channel

Beckman Coulter and hc1.com Enter Strategic Partnership for Innovative Healthcare Cloud System

The diagnostics division of Beckman Coulter (Brea, CA, USA) and hc1.com (Indianapolis, IN, USA) have announced a partnership to bring an innovative healthcare cloud-technology system to clinical laboratories. The system, hc1.com's "Healthcare Relationship Cloud," helps turn large amounts of clinical data into actionable... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.